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| INTRODUCTION
The direct Xa-inhibitors are attractive anticoagulants relative to traditional anticoagulants.
1 Post-regulatory studies, along with real-world studies, suggest that these direct oral anticoagulants (DOACs) are safe and effective, 2-4 however, since their availability in clinical practice there has been some debate about whether the one-size-fits-all approach with these agents is the best way to use them. 5, 6 A particular cohort of patients where uncertainty exists with this dosing strategy are those patients at the extremes of weight. In their summary of product characteristics, the manufacturers of rivaroxaban state that in patients who are at the extremes of weight (<50 kg or >120 kg), only a small influence of weight on patients' rivaroxaban plasma concentrations (<25%) is observed and no dose adjustment is necessary.
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This conclusion is derived from a small pharmacokinetic study in 36 healthy volunteers, administered 10 mg of rivaroxaban 8 ; how well the results from such a study translate to clinical outcomes is difficult to determine. The lack of robust data has left clinicians wondering if the fixed dosing strategy truly is sufficient for those in obese category class II or III and perhaps too much for patients <50 kg.
With the prevalence of obesity increasing substantially in recent years, obese patients are no longer exceptional in clinical practice.
This issue is particularly relevant in the acute management of venous thromboembolism (VTE), where it's important to efficiently manage the thrombosis and prevent further morbidity and mortality. Equally, more frail patients, and/or underweight patients are presenting to clinic with acute VTE and one questions the wisdom in prescribing the same dose that would be given to patients of no frailty, often larger individuals. The DOACs dosing strategy is very different to that employed by low molecular weight heparin (LMWH), where dosing is based on a mg/kg or IU/kg basis, despite the LMWHs having predictable pharmacokinetic profiles. 9 Weight is also a well-recognized covariant, impacting on the response to warfarin therapy.
10
Whilst pharmacokinetic studies and pharmacokinetic models already exist for rivaroxaban, 11-14 they do not currently provide sufficient evidence for clinicians prescribing for patients at the extremes of weight, in determining whether the doses are safe and effective. In recent years, both a sub-analysis of the Einstein Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) studies 15 and a UK study 16 Clinicians need more robust data before they can be sure of the optimal dosing strategy of each individual DOAC in this particular cohort of patients. In our hospital, rivaroxaban is the first line agent for the management of VTE and we wanted to begin to better understand the relationship between body weight and rivaroxaban exposure, particularly for the management of acute VTE.
| OBJECTIVES
To develop a pharmacokinetic model for rivaroxaban, based on realworld patients, specifically focusing on the impact of patients' body weight on rivaroxaban pharmacokinetics.
| METHODS

| Study setting and recruitment
This study saw collaboration between the departments of haematology and orthopaedic surgery at King's College Hospital (KCH). KCH is
Essentials
• The optimal dosing strategy of rivaroxaban for patients at the extremes of body weight is not known.
• A pharmacokinetic study was conducted based in real-world patients in a London teaching hospital.
• In the cohort of patients studied, weight on its own did not impact significantly on rivaroxaban pharmacokinetics.
• A larger study with patients in the weight categories of interest from the real-world population is required to further clarify the situation. For the orthopaedic population, eligible patients were identified soon after their procedure on the orthopaedic ward. For the VTE population, eligible patients were identified following a positive diagnosis through either the outpatient DVT service or thrombosis clinic in the haematology department.
All patients provided informed written consent prior to participation. At the time of consent, all participants were given a book to record the exact times they took their rivaroxaban tablets each day until they were seen by SB for the index study visit for blood sampling.
Where doses were missed (if any), patients were asked to record these in the book provided by SB.
| Blood sampling
Subjects were asked to take their rivaroxaban tablets at a specific 
| Sampling handling and analysis
Anti-Xa activity was used to characterize the rivaroxaban concentration. For determination of anti-Xa activity, 2.7 mL blood (9 vol) sample was collected in 0.109 M (3.2% trisodium citrate) Becton-Dickinson
Vacutainer. Following collection, the sample was centrifuged in a Rotina 420 R centrifuge (Hettich Zentrifugen) and double spun for 7 minutes at 2500 g and frozen within 1 hour of sample collection. The samples were stored at −40°C until analyzed. Samples were thawed and analyzed in weekly batches using the STA anti-Xa assay (Diagnostica Stago, Asnieres-sur-Seine, France), with appropriate rivaroxaban calibrators and controls, on the STA-R evolution analyzer (Diagnostica Stago) in the laboratory at King's College Hospital. Results were reported as ng/mL.
The lower and upper limits of quantification for this assay are <20 ng/mL and >500 ng/mL, respectively. This functional assay has been shown to correlate well with analysis conducted using turbulent flow liquid chromatography with high-resolution mass spectrometry. 
| Analysis and PK modelling
Pharmacokinetic (PK) analysis was conducted using the method of nonlinear mixed effects modelling. Population PK modelling fits mathematical models to describe pharmacokinetic data that arises from more than one individual. 21 The method does not require each subject to provide sufficient data to characterize their own PK profile, as PK information is shared between individuals to develop the population PK profile. 21 The method therefore allows the use of sparse sampling study designs, having an obvious advantage when applied in the clinic setting. A typical population PK model integrates both a covariate and a statistical model. 22, 23 The covariate model describes relationships between PK parameters and patient characteristics. The statistical model describes the variance in PK between and within individuals as well as residual variance due to biological variability, measurement errors, and errors in the fit of the model to the data.
| Developing the rivaroxaban model
Initially, several structural base models were developed, eg, a oneand two-compartment model and the model which best fit the data was selected. Goodness-of-fit plots, a statistical improvement in the fit of the model to the data using the objective function (minus twice the log-likelihood of the data), assessment of the precision of the parameter estimates, and residual variability were the criterion used to evaluate and choose the base model to take forward for full covariate analysis. The specific covariates evaluated as part of this analysis were those which had a mechanistic meaning: age, weight, BMI, lean body- Both the base and the final models were evaluated using a nonparametric bootstrap procedure (1000 replicates). 24 The final model was additionally evaluated using a visual predictive check, 25 where the 5th, 50th, and 95th prediction intervals, simulated from the posterior distribution of the final model parameter estimates were overlaid with the 5th, 50th, and 95th percentiles from the observed data. A wellperforming model would see the observed percentiles and simulated prediction intervals superimposed.
Pharmacokinetic analysis was conducted using NONMEM (ICON plc, Dublin, Ireland) version 7.2.13 26 and graphical analysis associated with the PK modelling and simulation was conducted using "R" version 2.14.1.40. 
| Ethical approval
| RESULTS
During the recruitment period (June 1, 2013-April 30, 2014), 101 patients consented to take part in the study. Demographic information on these patients is presented in Table 1 . Ninty-seven patients were either being managed for acute VTE or the secondary prevention of VTE and 4 patients were prescribed prophylactic rivaroxaban in the context of elective orthopaedic surgery prophylaxis. The 101 subjects provided 193 samples for PK modelling purposes, 24 patients (24%) providing 3 samples at the index study visit, 45 patients providing 2 samples (44%), and 32 subjects (32%) providing 1 sample. Figure 1 illustrates the breadth of samples generated in this study, in relation to body weight, and Figure 2 illustrates the breadth of concentrations in relation to time after dose of the samples generated by this study. Of these, 14 samples were below or above the level of quantification (BLQ or ALQ) of the assay being utilized. ALQ or BLQ were handled using a mixed-method approach. For BLQ <20 ng/mL, where results were obtained from the analyzer, these were entered into the model as reported, otherwise half BLQ (0.10 ng/mL) were entered into the dataset.
ALQ values (>500 ng/mL) were entered into the dataset, as 500 ng/mL.
The total BLQ or ABL for the dataset comprised <10% of the total dataset, and research suggests that when this is the case, that no one single approach is superior for handling BLQ/ABL for PK modelling purposes. 
| Rivaroxaban base model development
Several base models were initially explored (ie, one-and two-compartment models). A one-compartment model with between-subject variability on rivaroxaban clearance and volume of distribution with a combined (additive and proportional) error model best fitted the data ( creatinine clearance on clearance met the criteria for inclusion to the final model.
The final rivaroxaban PK estimates for typical values of CL and V d
thus can be represented mathematically as: Table 4 provides the estimates for the PK parameters for the final model developed.
Finally, a visual predictive check was conducted (Figure 3) , demonstrating a well-performing rivraoxaban PK model. 
T A B L E 3 Univariate covariate addition to the base model
| DISCUSSION
This study aimed to develop a PK model for rivaroxaban derived from real-world patients, with a particular focus on body weight. From the dataset generated, a relatively well-performing PK model for rivaroxaban was developed (Table 5 in comparison to PK models published by the manufacturers of rivaroxaban) and the data suggests that the single best co-variant predicting rivaroxaban exposure is creatinine clearance.
Elimination of rivaroxaban is via a dual pathway: renal excretion and metabolic degradation. Approximately 1/3 of rivaroxaban is eliminated as unchanged active drug in the urine, with active renal secretion accounting for 30% and glomerular filtration for 6%. The specific transporters involved with active renal secretion of rivaroxaban are P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). The remaining two-thirds of rivaroxaban is metabolized by several cytochrome P450 enzymes (CYP 3A4/5, CYP2J2) and CYP-independent mechanisms. 28 Given this, and the fact that active renal secretion predominates renal clearance, perhaps it's not surprising that renal function is the significant predictor of rivaroxaban exposure. It's also important to remember that this clearance mechanism is unique to rivaroxaban and what is reported here, may not be the case for the other currently available DOACs. We were surprised that weight did not feature more significantly as a covariant in our study. There are three possible rea- where weight in the present study was computed using a LBW equation, 29 and F = 1.04 for females and 1.23 for males.
Research suggests that both renal and liver activity increases in the obese, 30 therefore one might predict that clearance also increases in this from the clinical trials of rivaroxaban, and its questionable how well represented the extremes of weight were in these studies. Archillage and colleagues 16 assessed 167 acute VTE patients, stratified into three groups based on weight (<50 kg, 50-120 kg, >120 kg), with patients having rivaroxaban concentration measured 2-4 hours post dose (peak).
Patients were followed for a median of 14 months. The authors report that peak rivaroxaban plasma concentrations were significantly higher in patients with a lower body weight (<50 kg). Those patients with a weight >120 kg had comparable rivaroxaban peak concentrations to those of standard body weight. The authors also report that weight did not appear to impact on clinical outcomes. Although the results from this small study are encouraging, it's important to note that peak sampling is not considered the best time-point, when evaluating the clearance of a drug, which would be the case when wanting to evaluate the impact of weight. Trough sampling would have been more informative.
More recently a study in the setting of bariatric surgery, where prophylactic doses of rivaroxaban were given pre-and post-bariatric surgery, found single doses of rivaroxaban resulted in similar systematic drug exposures prior to and after bariatric surgery. 32 The median weights of patients in this study having sleeve gastrectomy was 137 kg (range 112-153) and 101.5 kg (range 96-120) for Roux-en-Y gastric bypass, ie, not excessively obese.
The findings from these afore-mentioned studies are reassuring, and in our study, we also found patients' rivaroxaban concentrations to be comparable when comparing the standard body weight patients and those in the obese category. The results of our study, should be considered in the context of their limitations. We conducted this study, at a time when experience with rivaroxaban was emerging and the agent had newly become available; the number of patients prescribed the drug in the extremes of weight category was less at the time of recruitment compared to our current practice now and that described in ISTH guidance. 17 Therefore, the number of patients in the extremes of weight categories in the present study, could have been greater.
Despite this, a well performing rivaroxaban model was developed and with further pharmacokinetic data coupled with outcome data, further direction to offer clinicians should be possible.
| CONCLUSION
Our study developed a pharmacokinetic model rivaroxaban model focusing on the impact body weight had on rivaroxaban exposure across a wide weight range, derived from a real-world population. Our study suggests that weight on its own is not a good predictor of rivaroxaban exposure, and found renal function computed by the Cockcroft-Gault equation to be a significant covariant explaining rivaroxaban exposure.
Further studies with larger data-sets from the extremes of weight cohort of patients will confirm/refute the findings from our work.
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